Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases
Authors:
Open Access
- 4 July 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1620152
Abstract
Cardiovascular diseases (CVDs) have emerged as one of the leading causes of global mortality and health burden, with their prevalence and mortality rates demonstrating a persistent upward trend, thereby posing significant challenges to public health worldwide. Tanshinone IIA (Tan IIA), the principal lipophilic bioactive component isolated from Salvia miltiorrhiza Bunge, has gained substantial recognition in cardiovascular therapeutics. Accumulating evidence from recent investigations has demonstrated that Tan IIA exhibits multi-target pharmacological properties and modulates diverse signaling pathways in cardiovascular protection, positioning it as a promising candidate in natural product-based drug discovery. The therapeutic efficacy is mediated through multiple mechanisms, including but not limited to anti-atherosclerotic effects, lipid homeostasis regulation, anti-arrhythmic properties, myocardial functional enhancement, and hemodynamic stabilization. This comprehensive review systematically elucidates the molecular mechanisms and therapeutic targets underlying Tan IIA’s cardio-protective effects, particularly focusing on its anti-inflammatory, antioxidant, anti-atherosclerotic, and myocardial preservation properties. Furthermore, we critically evaluate its current clinical applications and propose potential directions for future research to optimize its therapeutic potential in cardiovascular medicine.Keywords
Funding Information
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
This publication has 190 references indexed in Scilit:
- Novel Electroactive Therapeutic Platforms for Cardiac Arrhythmia ManagementAdvanced Science, 2025
- Oxidative stress disrupts vascular microenvironmental homeostasis affecting the development of atherosclerosisCell Biology International, 2024
- Inflammation‐Targeted Nanomedicines Alleviate Oxidative Stress and Reprogram Macrophages Polarization for Myocardial Infarction TreatmentAdvanced Science, 2024
- Tanshinone IIA ameliorates experimental diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress in cardiomyocytes via SIRT1Phytotherapy Research, 2023
- Tan IIA mitigates vascular smooth muscle cell proliferation and migration induced by ox‐LDL through the miR‐137/TRPC3 axisThe Kaohsiung Journal of Medical Sciences, 2023
- Efficacy of Sodium Tanshinone IIA Sulfonate in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Controlled, Randomized TrialCardiovascular Drugs and Therapy, 2020
- The regulated profile of noncoding RNAs associated with inflammation by tanshinone IIA on atherosclerosisJournal of Leukocyte Biology, 2020
- Tanshinone IIA inhibits the adipogenesis and inflammatory response in ox‐LDL‐challenged human monocyte‐derived macrophages via regulating miR‐130b/WNT5AJournal of Cellular Biochemistry, 2019
- Sodium tanshinone IIA sulfonate prevents hypoxic trophoblast‐induced endothelial cell dysfunction via targeting HMGB1 releaseJournal of Biochemical and Molecular Toxicology, 2017
- Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP‐9 activity through AKT signaling pathwayJournal of Cellular Biochemistry, 2007